Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eqrx Inc (EQRX)

Eqrx Inc (EQRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,140,551
  • Shares Outstanding, K 487,415
  • Annual Sales, $ 0 K
  • Annual Income, $ -169,090 K
  • EBIT $ -385 M
  • EBITDA $ -393 M
  • 60-Month Beta 0.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.97
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.55
  • Most Recent Earnings $-0.15 on 08/08/23
  • Next Earnings Date 11/09/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +555,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.01 +16.42%
on 10/30/23
2.63 -10.86%
on 11/03/23
+0.12 (+5.41%)
since 10/06/23
3-Month
2.01 +16.42%
on 10/30/23
2.63 -10.86%
on 11/03/23
+0.10 (+4.46%)
since 08/08/23
52-Week
1.58 +48.10%
on 05/02/23
5.55 -57.84%
on 11/09/22
-3.22 (-57.91%)
since 11/08/22

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCCI, EQRX, CFMS

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

HCCI : 45.51 (+0.09%)
EQRX : 2.34 (-2.09%)
CFMS : 2.26 (unch)
Shareholder Alert: Ademi LLP investigates whether EQRx, Inc. has obtained a Fair Price in its transaction with Revolution Medicines

/PRNewswire/ -- Ademi LLP is investigating EQRx (Nasdaq: EQRX) for possible breaches of fiduciary duty and other violations of law in its transaction with...

EQRX : 2.34 (-2.09%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, EQRX, RVMD

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

RETA : 172.36 (+0.02%)
EQRX : 2.34 (-2.09%)
RVMD : 44.39 (+1.05%)
EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders

Shareholder rights law firm Robbins LLP is investigating EQRx, Inc. (NASDAQ: EQRX) to determine whether certain EQRx officers and directors violated securities laws and breached fiduciary duties to shareholders....

EQRX : 2.34 (-2.09%)
Pre-Market Brief: Stocks Mixed As Focus Shifts to Fed Warning

December S&P 500 futures (ESZ22) are trending down -0.40% this morning after three major US benchmark indices closed higher on Friday, demonstrating their strongest weekly advance in almost five months...

ESZ22 : 3,871.47s (-0.66%)
SOND : 3.22 (-2.42%)
OKTA : 83.19 (-0.49%)
D : 53.77 (+0.17%)
FLGT : 18.51 (-0.43%)
EQRX : 2.34 (-2.09%)
Why EQRx Shares Dropped 28.62% on Thursday

The company suspended trials for one of its lead therapies.

EQRX : 2.34 (-2.09%)
EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress

Initiated a U.S.-led, comparative Phase 3b clinical trial with aumolertinib for the first-line treatment of EGFR-mutated NSCLCAnnounced U.K. MHRA...

EQRX : 2.34 (-2.09%)
EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a...

EQRX : 2.34 (-2.09%)
EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

Marketing authorization application is EQRx’s first submission to a regulatory agencyApplication is based on data from pivotal Phase 3 AENEAS trial in the...

EQRX : 2.34 (-2.09%)
EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022

In a Phase 3 clinical trial, the addition of sugemalimab to chemotherapy improved median overall survival by 8.5 months versus placebo plus chemotherapy in...

EQRX : 2.34 (-2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

EQRx Inc. is a pharmaceutical company is involved in developing and delivering medicines to patients. EQRx Inc., formerly known as CM Life Sciences III, is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 2.50
2nd Resistance Point 2.46
1st Resistance Point 2.40
Last Price 2.34
1st Support Level 2.30
2nd Support Level 2.26
3rd Support Level 2.20

See More

52-Week High 5.55
Fibonacci 61.8% 4.03
Fibonacci 50% 3.57
Fibonacci 38.2% 3.10
Last Price 2.34
52-Week Low 1.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar